CIK 0001228627
- Non-accelerated filer
- Smaller reporting company
Opus Genetics, Inc.
Sign in to watch- Ticker
- IRD
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 113516358
- Phone
- +1 984-884-6030
- Business address
- 8 DAVIS DRIVE, SUITE 220, DURHAM, NC, 27713
- Former names
- Ocuphire Pharma, Inc., REXAHN PHARMACEUTICALS, INC., CORPORATE ROAD SHOW DOT COM INC, FERRARO FRANK
- 4 Option exercise Director acquired 1,574 shares (option exercise)
- 4 Option exercise Director acquired 1,574 shares (option exercise)
- 4 Option exercise Director acquired 787 shares (option exercise)
- 4 Option exercise Director acquired 3,148 shares (option exercise)
- 4 Option exercise President and CEO acquired 1,023 shares (option exercise)
- 4 Grant or award Director acquired 18,711 shares (grant or award)
- 4 Grant or award Director acquired 23,653 shares (grant or award)
- 4 Grant or award Director acquired 14,108 shares (grant or award)
- 4 Grant or award Director acquired 9,900 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market buy Director bought 5,000 shares at $1.99 ($9,950)
- 4 Open-market buy President and CEO bought 25,000 shares at an average $2.05 ($51,179)
- 4 Derivatives Options or other derivatives
- 4 Grant or award Director acquired 3,395 shares (grant or award)
- 4 Grant or award Director acquired 4,629 shares (grant or award)
Page 8 of 21 · 403 filings